Journal Mobile Options
Table of Contents
Vol. 79, No. 2, 2010
Issue release date: February 2010

Harm Avoidance as a Mediator of Treatment Response to Antidepressant Treatment of Patients with Major Depression

Quilty L.C. · Godfrey K.M. · Kennedy S.H. · Bagby R.M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: The temperament harm avoidance (HA) has consistently demonstrated an association with major depressive disorder (MDD), serotonin functioning and reduction in depression symptoms in response to antidepressant medications targeting the serotonin system. In the current investigation, we examine HA as a potential mediator of treatment response to a serotonergic tricyclic antidepressant. Methods: Outpatients (n = 150) with MDD were randomized to receive clomipramine or a control treatment. Patients completed the Hamilton Rating Scale for Depression (Ham-D) and the Tridimensional Personality Questionnaire (TPQ) prior to treatment initiation, and then again after at least 8 weeks of treatment. Using structural equation modeling, we evaluated a ‘mediation model’ in which change in HA is a mechanism of depression change in response to clomipramine, and a ‘complication model’ in which reduction in HA is a by-product of depression change. Results: The mediation model provided a good fit to the data by all indices, whereas the complication model did not. Patients treated with clomipramine exhibited a greater decrease in HA as compared to those in the control group; moreover, HA reduction was associated with depression reduction. Conclusions: HA mediated the response to antidepressant treatment, such that any treatment effect of clomipramine occurred through HA reduction. Although replication with multiple assessment periods is required to determine if HA reduction actually precedes depression reduction, the results contribute to a growing body of literature implicating personality constructs subsumed within negative emotionality as mediators of treatment response to medications targeting serotonergic functioning.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Nash J, Nutt D: Antidepressants. Psychiatry2007;6:289–294.

    External Resources

  2. Mann JJ: Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 1999;21:99S–105S.
  3. Owens MJ, Nemeroff CB: Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994;40:288–295.
  4. Schloss P, Williams DC: The serotonin transporter: a primary target for antidepressant drugs. J Psychopharmacol 1998;12:115–121.
  5. Nestler EJ, Barrot M, DiLeone RL, Eisch AJ, Gold SJ, Monteggia LM: Neurobiology of depression. Neuron 2002;34:13–25.
  6. Nelson EC, Cloninger CR, Przybeck TR, Csernansky JG: Platelet serotonergic markers and Tridimensional Personality Questionnaire measures in a clinical sample. Biol Psychiatry 1996;40:271–278.
  7. Hansenne M, Ansseau M: Harm avoidance and serotonin. Biol Psychol 1999;51:77–81.
  8. Peirson AR, Heuchert JW, Thomala L, Berk M, Plein H, Cloninger CR: Relationship between serotonin and the Temperament and Character Inventory. Psychiatry Res 1999;89:29–37.
  9. Cloninger CR: A unified biosocial theory of personality and its role in the development of anxiety states. Psychiatr Dev 1986;4:167–226.
  10. Cloninger CR: A systematic method for clinical description and classification of personality variants: a proposal. Arch Gen Psychiatry 1987;14:573–588.
  11. Cloninger CR, Przybeck TR, Svrakic DM: The Tridimensional Personality Questionnaire: US normative data. Psychol Rep 1991;69:1047–1057.
  12. Cloninger CR, Przybeck TR, Svrakic DM, Wetzel RD: The Temperament and Character Inventory (TCI): A Guide to Its Development and Use. St Louis, Center for Psychobiology of Personality, 1996.
  13. Hansenne M, Pitchot W, Gonzalez-Moreno A, Machurot PY, Ansseau M: The Tridimensional Personality Questionnaire (TPQ) and depression. Eur Psychiatry 1998;13:101–103.
  14. Hansenne M, Reggers J, Pinto E, Kjiri K, Ajamier A, Ansseau M: Temperament and Character Inventory (TCI) and depression. J Psychiatr Res 1999;33:31–36.
  15. Joffe RT, Bagby RM, Levitt AJ, Regan JJ, Parker JD: The Tridimensional Personality Questionnaire in major depression. Am J Psychiatry 1993;150:959–960.
  16. Mulder RT: Personality pathology and treatment outcome in major depression: a review. Am J Psychiatry 2002;159:359–371.
  17. Stallings MC, Hewitt JK, Cloninger CR, Heath AC, Eaves LJ: Genetic and environmental structure of the Tridimensional Personality Questionnaire: three for four temperament dimensions? J Pers Soc Psychol 1996;70:127–140.
  18. Herbst JH, Zonderman AB, McCrae RR, Costa PT: Do the dimensions of the Temperament and Character Inventory map a simple genetic architecture? Evidence from molecular genetics and factor analysis. Am J Psychiatry 2000;157:1285–1290.
  19. Bagby RM, Quilty LC, Ryder A: Personality and depression. Can J Psychiatry 2008;53:14–25.
  20. Quilty LC, Meusel LAC, Bagby RM: Neuroticism as a mediator of treatment response to SSRIs in major depressive disorder. J Affect Disord 2008;111:67–73.
  21. Costa PT, McCrae RR: Revised NEO Personality Inventory (NEO-PI-R) and NEO Five-Factor Inventory (NEO-FFI) Professional Manual. Odessa, Psychological Assessment Resources, 1992.
  22. De Fruyt F, Van De Wiele L, Heeringen CV: Cloninger’s psychobiological model of temperament and character and the five-factor model of personality. Pers Individ Dif 2000;29:441–452.
  23. Markon KE, Krueger RF, Watson D: Delineating the structure of normal and abnormal personality: an integrative hierarchical approach. J Pers Soc Psychol 2005;88:139–157.
  24. De Fruyt F, Van Leeuwen K, Bagby RM, Rolland J, Rouillon F: Assessing and interpreting personality change and continuity in patients treated for major depression. Psychol Assess 2006;18:71–80.
  25. Spitzer RL, Williams JB, Gibbon M: Structured Clinical Interview for DSM-III-R (SCID). New York, New York State Psychiatric Institute, Biometrics Research, 1987.
  26. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
  27. Gupta S, Nihalani N, Masand P: Duloxetine: Review of its pharmacology, and therapeutic use in depression and other psychiatric disorders. Ann Clin Psychiatry 2007;19:125–132.
  28. Bech P, Kajdasz DK, Porsdal V: Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology 2006;188:273–280.
  29. Bagby RM, Ryder AG, Schuller DR, Marshall MB: The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry 2004;161:2163–2177.
  30. Bech P, Gram LF, Dein E, Jacobsen J, Vitget J, Bolwig TG: Qualitative rating of depressive states. Acta Psychiatr Scand 1975;51:161–170.
  31. Arbuckle JL: Amos 6.0 User’s Guide. Spring House, Amos Development, 2005.
  32. Hu L, Bentler PM: Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equation Model 1999;6:1–55.

    External Resources

  33. Kline RB: Principles and Practice of Structural Equation Modeling, ed 2. New York, Guilford, 2005.
  34. Shrout PE, Bolger N: Mediation in experimental and nonexperimental studies: new procedures and recommendations. Psychol Methods 2002;7:422–445.
  35. Kraemer HC, Wilson GT, Fairburn CG, Agras WS: Mediators and moderations of treatment effects in randomized clinical trials. Arch Gen Psychiatry 2002;59:877–883.
  36. Carver CS, Miller CJ: Relations of serotonin function to personality: current views and a key methodological issue. Psychiatry Res 2006;144:1–15.
  37. Schmitz A, Hennig J, Kuepper Y, Reuter M: The association between neuroticism and the serotonin transporter polymorphism depends on structural differences between personality measures. Pers Individ Dif 2007;42:789–799.

    External Resources

  38. Van HL, Dekker J, Peen J, van Aalst G, Schoevers RA: Identifying patients at risk of complete nonresponse in outpatient treatment of depression. Psychother Psychosom 2008;77:358–364.
  39. Öngür D, Farabaugh A, Iosifescu DV, Perils R, Fava M: Tridimensional Personality Questionnaire factors in major depressive disorder: relationship to anxiety disorder comorbidity and age of onset. Psychother Psychosom 2005;74:173–178.
  40. Hetrick SE, Parker AG, Hickie IB, Purcell R, Yung AR, McGorry PD: Early identification and intervention in depressive disorders: towards a clinical staging model. Psychother Psychosom 2008;77:263–270.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50